Patient / Study Participant Information
RESEARCH- Patient / Participant Information
Through participation in research studies, at Maine Cardiology Associates we are able to provide you with the newest, most advanced therapies that may not be available in all hospitals or clinics. Based on our excellent reputation in our field, Maine Cardiology has been selected to participate in investigations that advance our knowledge and improve treatment for patients with heart disease.
Are there benefits to participating in a research study?
Many of the studies we participate in are supported by private industry or other grants. This allows participants to receive research related medication, diagnostic testing, and physician assessments at no cost. Other benefits include ongoing education as well as frequent contact with the research team. Sometimes patients are also paid for participation in research.
Are there risks involved in research studies?
Any treatment or test, even those widely used or accepted involves some level of risk. While the study provides newer treatments that might otherwise be unavailable, there is no guarantee that each and every patient will benefit from participating in a research study. All research conducted at Maine Cardiology Associates is approved by and overseen by an ethics committee known as an institutional review board or IRB. The IRB ensures that the rights of the participants are enforced and that the potential risks involved do not out-weigh the potential benefits.
How do I decide whether or not to participate in a research study?
Feel free to discuss research with your cardiologist or a member of our research staff. If you choose not to become involved in a research study, your care will not be affected in any way. Research participation is voluntary.
Currently Enrolling Studies
| Study Title |
For Patients With |
| CSPP100A2353: A 12 week, double-blind, randomized, parallel group,
multi-center study to evaluate the efficacy and safety of the combination of
aliskiren 300 mg and hydrochlorothiazide 25 mg compared to aliskiren 300 mg in patients
with stage II hypertension |
Treated or untreated hypertension (high blood pressure) |
| CDx000004: Identification of Gene Expression Patterns in Circulating
Cells that Predict the Presence of Coronary Artery Disease |
Elective cardiac catheterization / coronary angiography |
| RED-HF- Reduction of Events with Darbepoetin alfa in Heart Failure Trial to evaluate the treatment of anemia in subjects with symptomatic left ventricular systolic dysfunction |
Congestive Heart Failure and Anemia |
| TRA2P TIMI 50 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SCH530348 in Addition to Standard of Care in Subjects With a History of Atherosclerotic Disease: Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events |
History of heart attack, stroke, or peripheral vascular disease |
| Protocol 127-014: A Phase 3 Clinical Trial to Assess Perfusion and obstruction Identified by Non-invasive Technology using PB127 Ultrasound Contrast Agent in Patients with Suspected Obstructive Coronary Artery Disease II |
Undergoing Nuclear Stress Testing |
| Randomized, Double-Blind, Double-Dummy, Parallel Group,
Phase 3 Efficacy and Safety RESEARCH Study of CGT-2168 Compared with Clopidogrel
to Reduce Upper Gastrointestinal Events
including Bleeding and Symptomatic Ulcer Disease |
Recent stent placement and/or acute coronary syndrome |
Questions and Contact Information
If you have questions about currently enrolling studies or research in general, please contact the Research Department at (207)523-4630 or via e-mail at
tim.bilodeau@mainecardiology.com.
TO BE CONSIDERED FOR FUTURE STUDIES, PLEASE SEND AN E-MAIL WITH YOUR NAME, PHONE NUMBER, AND A LIST OF THE KINDS OF STUDIES YOU ARE INTERSTED IN TO tim.bilodeau@mainecardiology.com.
